An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Regular-moderate intensity exercise, while avoiding very intense exercise is probably best for people in their 70s.

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of ...

Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more ...

NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.